Last reviewed · How we verify
NCT02042989
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Completed
Phase 1
Last updated 11 July 2022
What this trial tests
Phase 1 trial testing MLN9708 in Advanced Cancers in 68 participants. Completed in 22 January 2020.
Timeline
27 June 2014
Primary endpoint
22 January 2020
22 January 2020
22 January 2020
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 68 |
| Start date | 27 June 2014 |
| Primary completion | 22 January 2020 |
| Estimated completion | 22 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MLN9708 — full drug profile →
- Vorinostat (VORINOSTAT) — full drug profile →
Conditions studied
- Advanced Cancers — all drugs for Advanced Cancers →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Advanced Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting autophagy in cancer.
Levy JMM, Towers CG, Thorburn A. · · 2017 · cited 2029× · PMID 28751651 · DOI 10.1038/nrc.2017.53 -
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X, Zhang T, Su W, Dou Z, et al · · 2022 · cited 304× · PMID 36400749 · DOI 10.1038/s41419-022-05408-1 -
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.
Li G, Tian Y, Zhu WG. · · 2020 · cited 246× · PMID 33117804 · DOI 10.3389/fcell.2020.576946 -
Autophagy and Autophagy-Related Diseases: A Review.
Ichimiya T, Yamakawa T, Hirano T, Yokoyama Y, et al · · 2020 · cited 240× · PMID 33255983 · DOI 10.3390/ijms21238974 -
Synergies in exosomes and autophagy pathways for cellular homeostasis and metastasis of tumor cells.
Salimi L, Akbari A, Jabbari N, Mojarad B, et al · · 2020 · cited 102× · PMID 32426106 · DOI 10.1186/s13578-020-00426-y -
The Function of the Mutant p53-R175H in Cancer.
Chiang YT, Chien YC, Lin YH, Wu HH, et al · · 2021 · cited 82× · PMID 34439241 · DOI 10.3390/cancers13164088 -
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Tundo GR, Sbardella D, Santoro AM, Coletta A, et al · · 2020 · cited 78× · PMID 32442437 · DOI 10.1016/j.pharmthera.2020.107579 -
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S, Iwakuma T. · · 2023 · cited 77× · PMID 36672377 · DOI 10.3390/cancers15020429
Verify or expand the search:
- PubMed search for NCT02042989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MLN9708
Trials testing the same drug.
- NCT03731832 — Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory · Phase 2 · completed
- NCT02477215 — Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma · Phase 1, PHASE2 · completed
- NCT02384746 — Phase I Study of the Combination of MLN9708 and Fulvestrant · Phase 1 · terminated
- NCT02169791 — Nonmyeloablative Haploidentical Transplant Followed by MLN9708 · Phase 2 · completed
- NCT02057640 — MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma · Phase 1, PHASE2 · completed
Other recruiting trials for Advanced Cancers
Currently open trials in the same condition.
- NCT06001749 — Psilocybin in Cancer Pain Study · Phase 2 · recruiting
- NCT03375983 — Plasmodium Immunotherapy for Advanced Cancers · Phase 1, PHASE2 · recruiting
- NCT01375114 — The Effects of Ginseng on Cancer-Related Fatigue · Phase 1, PHASE2 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02042989 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02042989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing